Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAX028 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| QAX028 high dose | EXPERIMENTAL | - |
| QAX028 low dose | EXPERIMENTAL | - |
| Tiotropium | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | ACTIVE_COMPARATOR | QAX028 high dose |
| 2 | PLACEBO_COMPARATOR | Placebo |
| 3 | ACTIVE_COMPARATOR | Tiotropium bromide |
| 4 | ACTIVE_COMPARATOR | QAX028 medium dose |
| 5 | ACTIVE_COMPARATOR | QAX028 low dose |
| Name | Type | Description |
|---|---|---|
| QAX028 | DRUG | QAX028 60 mcg via inhalation device |
| Tiotropium | DRUG | Tiotropium via inhalation device |
| Placebo | DRUG | Placebo to QAX028 via inhalation device |
| Tiotropium bromide | DRUG | - |
Inclusion Criteria: * Diagnosis of COPD according to GOLD guidelines * Post-bronchodilator 30%≤FEV1\<80% of predicted normal and ost-bronchodilator FEV1/FVC \<0.7 * Smoking history of at least 10 pack years Exclusion Criteria: * Requiring oxygen therapy on a daily basis * Exacerbation of airway d...
QAX028 is an investigational small molecule being developed for chronic obstructive pulmonary disease (COPD). It has been studied in patients with mild-to-moderate COPD to evaluate its safety, tolerability, and pharmacodynamics, as well as its efficacy compared with placebo and an active control.
QAX028 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. Novartis has sponsored clinical trials of QAX028 in patients with COPD.
QAX028 has completed Phase 1 and Phase 2 clinical trials. The Phase 1 trial assessed safety and tolerability, while the Phase 2 trial evaluated safety and efficacy of multiple doses. Both trials are completed, and QAX028 remains an investigational drug.
QAX028 has been studied in two completed clinical trials. The first, NCT00568503, was a Phase 1 trial in Denmark enrolling 29 patients with mild-to-moderate COPD. The second, NCT01068613, was a Phase 2 trial in the United States enrolling 62 patients with COPD.
No, QAX028 is not the same as tiotropium bromide. In a Phase 1 trial, QAX028 was compared with open-label tiotropium bromide and placebo to assess its safety, tolerability, and pharmacodynamics in patients with mild-to-moderate COPD. QAX028 is a separate investigational compound.